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Background: Patients’ expectations of treatment effects may contribute to positive (placebo) and negative
(nocebo) outcomes. The effect of patient expectations may be pronounced in subjectively assessed conditions,
such as male erectile dysfunction. The aim of this project is to examine the magnitude of expectancy in trials of
phosphodiesterase-5 inhibitors. We hypothesize that randomized controlled trials with inadequate blinding will
report enhanced placebo effects for intervention groups and nocebo effects for placebo groups, compared with
adequately blinded studies.
Methods/design: We will quantify the magnitude of expectancy by comparing the effect estimates of trials with
inadequate and adequate blinding. Blinding will be assessed using four domains from the Cochrane ‘risk-of-bias’
tool: allocation concealment; blinding of patient; caregiver; and outcome assessor. Our secondary aim is to identify
factors that can modify expectations, such as prior experience with the intervention and drug side effects.
We will perform an electronic search using a combination of controlled vocabulary and free text words in the
following databases: MEDLINE, EMBASE, CENTRAL, and a clinical trials register. We will include randomized
controlled trials, with either parallel or crossover design, that compare one phosphodiesterase-5 inhibitor with a
placebo. The study’s primary aim should be to investigate the efficacy of phosphodiesterase-5 inhibitors for treating
male erectile dysfunction. Screening will take place at two levels: abstracts and titles, followed by full text reports.
Two reviewers will independently extract data on the primary outcome and assess risk of bias.
We will meta-analyze treatment effects, if appropriate, to assess the magnitude of enhanced placebo effects and
nocebo effects in intervention and placebo groups, respectively. We will explore possible mediators of placebo and
nocebo effects with subgroup and meta-regression analyses.
Discussion: Treatments may confer significant costs and risk of adverse effects; it is important, therefore, to
determine whether the effects of treatments are larger than expectancy alone. If treatment expectations can be
used in a non-deceptive way to produce clinically advantageous outcomes, then it may be possible to incorporate
such mechanisms into evidence-based healthcare decision-making.
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A particular treatment effect may exert both non-
specific and specific effects. A non-specific treatment ef-
fect is an outcome that does not arise according to an
intended mechanism of action. This can be a response
to a placebo but can also reflect a spontaneous symptom
improvement. A placebo is usually thought of as a sugar
pill, but placebos can come in any form; they may be
things (syringes, medical devices), rituals (anamnesis, in-
gestion of drugs), places (hospital, doctor’s office), rela-
tionships (with doctor, self-help group), medical beliefs
to suggestive wordings [1]. The response to a placebo
can be either positive for the outcome of interest, de-
fined as a placebo effect, or negative for the outcome of
interest, defined as a nocebo effect.
These effects are commonly explained by expectancy
and conditional learning [2]. These two concepts over-
lap, so for convenience, we will use the term ‘expectancy’
to describe the mechanism behind placebo and nocebo
effects.
Studies have shown that expectations can induce very
powerful effects. In an experiment with an opioid pain-
killer, remifentanil, the presence of positive treatment
expectancies was found to double the analgesic effect.
Conversely, negative treatment expectancies interfered
with the analgesic potential of the painkiller to the ex-
tent that the analgesic effect was completely abolished
[3]. In a double-blind sham surgery trial, investigating a
new surgical transplant technique for treatment of Par-
kinson’s disease, sham and real surgery interventions were
equally effective. However, participants who thought they
received the transplant reported better quality of life [4].
It seems that positive expectations were triggered by the
perceived benefit from the treatment.
To control for the effects of expectations, the double-
blind randomized controlled trial (RCT) design is com-
monly employed to study a novel intervention for its
specific effects. Because neither participants nor investi-
gators know who gets the intervention or the placebo,
expectancies are balanced across groups. Double blind-
ing makes groups comparable so that specific and non-
specific treatment effects (that is, the effect size of the
placebo group) can be ascertained with less potential for
bias. Both intervention and placebo groups may have
two important expectations in common: ‘I get the inter-
vention or the placebo,’ and ‘The intervention under
study can cure my problem.’
However, there is little evidence that RCTs are, in fact,
double-blinded [5]. Many factors can undermine double-
blinded methodology, including poor randomization
methods, imperfect concealment of allocation, and the
use of a placebo that is distinguishable from the inter-
vention. Furthermore, in RCTs of pharmacological agents,
the presence of side effects may allow participants orinvestigators to guess correctly who has been allocated to
intervention or placebo [6]. Therefore, the use of an ac-
tive placebo that mimics some of the intervention’s side
effects has been advocated to improve clinical trial
blinding.
If an RCT is not double-blinded, participants and
investigators will know who gets what type of treat-
ment. Expectations, therefore, could become unbalanced
among treatment arms. A participant allocated to the
intervention would have altered expectations: ‘I get the
intervention’ and ‘The intervention under study can cure
my problem.’ This enhances the participant’s prior expec-
tations and can generate an enhanced placebo effect. For
participants receiving the placebo, expectations could be
‘I get the placebo,’ and ‘The intervention under study can
cure my problem.’ This can lower participants’ expecta-
tions and generate a nocebo effect.
This review will test the hypothesis that unblinding in
RCTs is associated with enhanced placebo effects for in-
tervention groups and nocebo effects for placebo groups.
We will investigate this research question by conducting
a meta-epidemiological study of phosphodiesterase-5
(PDE-5) inhibitors. For many years, this treatment has
been an established baseline treatment for erectile dys-
function (ED). Numerous trials, overviews, and system-
atic reviews provide evidence for the efficacy and safety
of sildenafil, tadalafil, and vardenafil. There is also a
growing evidence base for the newer molecules mirode-
nafil, udenafil, lodenafil, and avanafil. The PDE-5 inhibi-
tors have been tested in many different populations,
including those with broad-spectrum and specific
comorbid conditions. The role of treatment expectations
is of particular relevance to these medications for sev-
eral reasons. Firstly, the evidence for efficacy relies
solely on subjectively assessed outcomes, such as self-
administered questionnaires (International Index of Erec-
tile Functioning (IIEF)), event logs, and a global efficiency
question (GEQ) [7]. Randomized control trials that use
these subjective outcome measures are especially vulner-
able to unblinding: non-blinded RCTs report 25% higher
estimates of treatment effects than their blinded counter-
parts [8]. Whether this can be explained by nocebo
effects in placebo groups or enhanced placebo effects for
intervention groups was not reported. Secondly, since
PDE-5 inhibitors are a well-tolerated and effective treat-
ment for ED, initial expectations to treat this common
male sexual problem are high for doctors, patients, and
drug companies. Lastly, as suggestion can create expect-
ancies [9], the domain of male sexual performance is a
very suggestive domain, where expectations can play a
fundamental role.
This meta-epidemiological study will explore mag-
nitude of expectancy and mediating factors in RCTs. If
the mechanisms mediating placebo effects such as
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We will use data from an earlier published systematic re-
view on PDE-5 inhibitors that included RCTs up to July
2006 [10]. This dataset will be updated for any missing
variables and for new reports. To ease clinical interpret-
ation of our findings, we will restrict our search to the
three agents approved by the Food and Drug Adminis-
tration (FDA): sildenafil, vardenafil, and tadalafil. We will
use the following methods to identify studies reported in
English, French, Dutch, or German since July 2006.
Our search strategy will employ a combination of con-
trolled vocabulary (MeSH terms) and free text words.
Three concepts will be combined (AND): the interven-
tion concept ‘PDE-5 inhibitor’, the disease concept ‘erect-
ile dysfunction,’ and the design concept ‘RCT.’ The latter
will be identified using the Cochrane Highly Sensitive
Search Strategy for identifying RCTs [11]. We will search
MEDLINE using PubMed, EMBASE, CENTRAL (The
Cochrane Central Register of Controlled Trials) and a
clinical trials register (clinicaltrials.gov). The PubMed/
MEDLINE search strategy is presented in Appendix 1 and
will be adapted to search the other electronic databases.
Selection of studies
One reviewer (FF) will manually screen the titles and
abstracts of search yields using pre-defined screening
questions to remove studies that are obviously irrelevant
to our topic (Appendix 2). The full texts of potentially
relevant reports will then be obtained. If multiple reports
for the same study exist, they will be linked to determine
eligibility. Two reviewers, a content area expert (FF) and
a methodologist (GEB), will independently screen full,
unblinded texts using a pilot-tested eligibility form
(Appendix 3). If there is disagreement among reviewers,
it will be recorded and resolved by discussion. The level
of agreement among reviewers will be quantified with a
kappa statistic. We will describe the selection of studies
in a flow diagram, as recommended by the PRISMA state-
ment (preferred reporting items for systematic reviews)
[12], and keep a list of excluded studies, with primary
reasons for exclusion.
We will screen studies according to the following in-
clusion criteria:
 Study design: RCTs with parallel or crossover design
that compare one PDE-5 inhibitor to placebo. The
study’s primary aim should be to investigate the
efficacy of PDE-5 inhibitors in treating male ED. Participants: Men ≥ 18 years old complaining of or
diagnosed with ED.
 Intervention: Treatment for ED with a PDE-5
inhibitor (sildenafil, vardenafil, tadalafil) at any dose
regimen.
 Comparison: placebo.
 Study reports numerical values for change from
baseline or baseline and final IIEF erectile
functioning (EF) scores for the placebo and
intervention groups separately.
Data extraction and risk-of-bias assessment
We will develop and pilot test electronic forms to ex-
tract data and assess risk of bias of all included study
reports. Items to be included in the data extraction form
are provided in Appendix 4. We will assess blinding
using four domains of the Cochrane’s ‘risk-of-bias’ tool
that relate to blinding: allocation concealment, blinding
of patient, blinding of caregiver, and blinding of outcome
assessor. In addition, the risk-of-bias assessment will in-
clude an evaluation of sequence generation, intention-to-
treat (ITT) analysis (quantified as the ratio of analyzed
versus allocated number of participants) and comparabil-
ity of treatment and placebo groups (for example, assess-
ment of baseline prognostic characteristics). For each
included study, we will rate the risk-of-bias domains as
low, high, or unclear. To improve accuracy, all primary
outcome data and risk-of-bias assessments will be in-
dependently extracted by a second reviewer (GEB). Dis-
agreements will be recorded and resolved by open
discussion.
Data analysis
Quantifying enhanced placebo and nocebo effects
We will quantify the magnitude of enhanced placebo
effects as the difference in treatment effect estimates
among studies with inadequate blinding and studies with
adequate blinding. Similarly, the magnitude of nocebo
effects will be quantified as the difference in placebo ef-
fect estimates among studies with inadequate and ad-
equate blinding.
Outcomes
The most commonly used outcome in efficacy studies
of PDE-5 inhibitors is the IIEF-EF domain score [13].
Therefore, we will use this outcome to assess effect sizes.
We will also assess GEQ, a common dichotomous out-
come, to confirm consistency of the effect. Our primary
and secondary outcomes are:
1. Primary: the IIEF-EF change from baseline score
from the validated IIEF questionnaire for placebo and
intervention groups separately (a continuous
subjective outcome assessed by patient). For the
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95% confidence intervals (CI) between change from
baseline IIEF-EF-scoreIntervention group and the change
from baseline IIEF-EF-scorePlacebo group will be
calculated. If only final and baseline IIEF-EF scores
are reported, we will assume change scores to be
final-minus-baseline scores. A sensitivity analysis for
this assumption will be performed.
2. Secondary: for placebo and intervention groups
separately:
2.a. GEQ (a dichotomous subjective outcome assessed
by patient). The risk ratio (RR) with 95% CIs will
be calculated.
2.b. Type and number of adverse events (AEs) reported.
At least the two most common AEs reported for
PDE-5 inhibitors: headache and flushing (a
continuous subjective outcome assessed by
clinician). The RR with 95% CIs will be calculated.
Only AE incidences, measured as single events
(that is, no count data), will be extracted.
For GEQ, all randomized participants will be included
in the analysis, irrespective of how the authors of the re-
port defined their ITT sample; therefore, all discontinua-
tions from the point of randomization will be considered
non-response.
We will impute missing data, such as standard devi-
ation, based on other available data, such as standard
error, 95% CI, t value, or P value. If imputation of miss-
ing data is not possible, we will contact the original
investigators to request missing data. If there is no re-
sponse, we will use data from matched studies.
Crossover study designs that report only first-phase
outcome data will be treated as a parallel RCT and
included in the main analysis. Studies that report only
final-outcome data will be included in a separate cross-
over study analysis. For studies that report data for two
phases separately, we will calculate the difference be-
tween first and second phases and use a t test for statis-
tical confirmation. If we find no difference, then we will
pool data and include them in a separate crossover stud-
ies analysis. If we find a difference, then we will extract
only first-phase data and treat the study as a parallel
study design to be included in the analysis.
As a secondary objective, we will explore moderating
variables of placebo and treatment effect estimates that
may explain enhanced placebo and nocebo effects. Of
particular interest are prior experience with medica-
tion, drug side effects, exclusion of placebo responders,
study run-in period, sample size, geographical location
of the study, single- or multi-center study, risk of bias,proportion of psychogenic etiology, prostate cancer or
spinal cord injury, funding source, publication year, base-
line disease severity, disease duration, study duration, and
number of follow-ups after baseline assessment.
Data synthesis
We will meta-analyze studies, if appropriate, using gen-
eric inverse variance. We plan to use a random-effects
model because we anticipate that the included studies
will show considerable clinical (broad-spectrum and spe-
cific comorbid populations; different PDE-5 inhibitors)
and methodological (study design, risk of bias) hetero-
geneity. The analysis will include all parallel RCTs and a
separate analysis will include crossover RCTs. For the
latter, we anticipate that carry-over effects can contrib-
ute to unblinding. Therefore, lower placebo and higher
treatment effects in crossover studies may be present
than in parallel studies only. We will pool data from
both study designs if no significant differences are found
between the separate analyses.
Variability in effect estimates that are due to hetero-
geneity rather than sampling error (that is, chance) will
be identified visually using a forest plot. The magnitude
of heterogeneity will be assessed by calculating I2 with
confidence interval and confirmed statistically with a
chi-square test with 0.10 significance level.
For every individual risk-of-bias domain, we will group
studies with low risk of bias and studies with unclear or
high risk of bias. Studies that have a low risk of bias
across all four risk-of-bias domains, and therefore con-
sidered adequately blinded, will be pooled and compared
with studies that have a high or unclear risk of bias
across all four risk-of-bias domains (Table 1). For both
groups, we will calculate pooled treatment and placebo
effect. The difference in effect estimates of placebo groups
between the two sets of studies will be the nocebo effect
and the difference in treatment effect estimates of in-
tervention groups will be the enhanced placebo effect.
Differences between groups will be quantified with a 95%
CI and then qualified statistically using a t test of no dif-
ference with P value. Between-meta-analysis heterogen-
eity variance will be calculated to express the variability
in bias with P value and identified visually using a for-
est plot. The magnitude of heterogeneity will be assessed
by calculating I2 and confirmed statistically with a chi-
square test with 0.10 significance level. We will assess
reporting bias by visually examining a funnel plot for
symmetry if there are a sufficient number of studies.
The comparison of adequately and inadequately
blinded studies is observational and, therefore, blinding
status is likely to be associated with other variables that
also influence within group treatment and placebo effect
estimates (that is, the association between blinding status
and effect estimates will be confounded). Using meta-
Table 1 Enhanced placebo effect and nocebo effect







































Blinding: participant . . . . . . . . . . . . . . . . . . . . .
Blinding: caregiver . . . . . . . . . . . . . . . . . . . . .
Blinding: outcome
assessor
. . . . . . . . . . . . . . . . . . . . .
Summary of four risk
of bias domains
. . . . . . . . . . . . . . . . . . . . .
CI, confidence interval; IV, inverse variance.
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ity and publication year as possible confounders and
present adjusted effect estimates for enhanced placebo
effect and nocebo effect.
To interpret nocebo effects in placebo groups and
enhanced placebo effects in intervention groups, we will
conduct the following analyses: examine forest plots
stratified according to risk of bias; interpret P value on
lack of these effects (P < 0.05 significance) and variability
in bias between subgroups; and explore clinical rele-
vance of these effects using reported minimal clinically
important differences (MCID) for IIEF-EF scores [14].
Assessment of adverse events on nocebo and enhanced
placebo effects
We expect a limited number of studies to be adequately
blinded so, for power considerations, we will explore
solely whether AEs can explain nocebo and enhanced
placebo effects. The type of AE that placebo groups re-
port seem to match AEs of intervention groups [15].
This is sometimes explained as a nocebo effect due to
the informed consent document. This document informs
study participants of the most common AEs (in the case
of PDE-5 inhibitors, the most common AEs are head-
ache and flushing) and sets out AE expectations that can
modify the rates of reported AEs [16]. This reporting
effect may also be enhanced by AE expectations of
outcome assessors. Differing AE rates in placebo and in-
tervention groups are believed to be a major determin-
ant in unblinding RCTs. Study participants reporting
many AEs may also enhance their expectations of re-
ceiving the intervention under study. This could explain
enhanced placebo effects. Conversely, lack of AEs can
lower expectations of receiving the intervention under
study, creating a nocebo effect. More concordant AE
rates (mathematically, we will use RRs) for placebo and
intervention groups may render the study less prone to
unblinding. Groups of studies with higher risk ofunblinding may be associated with higher RRs and thus
higher nocebo effects in placebo groups and enhanced
placebo effects in intervention groups.
Meta-regression and subgroup analyses
We will use meta-regression univariate and multivariate
analysis to investigate patient- and study-related vari-
ables that influence placebo and treatment effects. The
following variables will be explored:
1. Number of study follow-ups after baseline
assessments. Every follow-up involves an interaction
between study personnel and the participant. Any
(un)conscious modification of treatment outcome
expectation can potentially invalidate the double-
blind procedure. More frequent contact would then
translate into enhanced placebo effects, seen as
higher treatment effects, and nocebo effects, seen as
lower placebo effects [17].
2. Sample size.
3. Study duration.
4. Proportion of psychogenic etiology. Some evidence
suggests that participants having ED due to
psychological mechanisms report higher placebo effects.
5. Prostate cancer or spinal cord injury. These two
conditions are associated with low expectancy of EF.
We expect lower placebo and treatment effects.
6. Baseline ED severity (IIEF-EF score)
7. ED duration. The longer the ED exists, the lower
expectancy of recovery.
8. ITT analysis. Studies excluding participants from
analyses can result in biased effect sizes.
9. Publication year. Early reports can reflect data from
studies that have higher expectations about the new
treatment.
We will carry out subgroup analysis to measure the
impact of study, intervention, and patient factors on
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vestigate whether the effect is different in the case of
subgroups, the overlap in CIs of summary estimates will
be considered. An I2 statistic for between-subgroup het-
erogeneity will be calculated and a significance test per-
formed. If a sufficient number of studies can be included
in our main analysis, we may conduct some of the fol-
lowing subgroup analyses, with priority for the factor
‘prior PDE-5 inhibitor experience’.
Study factors:
1. Parallel studies only.
2. Crossover studies only. We anticipate that carry-over
effects can contribute to unblinding during RCTs.
Therefore, lower placebo and higher treatment
effects in crossover studies may be present than for
parallel studies only.
3. Study run-in phase with placebo (yes/no). During a
study run-in phase with placebo, participants and
study personnel know that placebo is given for every
participant. When the double-blind phase starts,
some participants are switched over to the
intervention and the remaining participants stay on
placebo. It can be hypothesized that the former
group suddenly experiences change of bodily cues,
owing to pharmacological effects of the intervention
(such as AEs), potentially augmenting their belief
that they are receiving the intervention. It can be
expected that this group report a larger treatment
effect, owing to higher expectations of treatment
benefit in comparison with an intervention group
that had no placebo run-in phase. In placebo groups,
prior experience with placebo is expected to lower
effects.
4. Commercial funding (yes/no). Commercially funded
studies may have a lower incentive to protect study
quality because higher study quality is associated
with smaller treatment effects [18]. We expect
commercial funding to be associated with lower
placebo and higher treatment effects.
5. Continent (America, Europe, Australia, Asia). Some
evidence suggests that placebo effects differ
according to geographical locations [19].
6. Single-center study (yes/no). In multi-center studies,
a centrally regulated organization conducts
important aspects of RCTs, such as generation of
randomization sequences, concealment of allocations,
and the preparation of study drugs. In single-center
studies, participants and study personnel all meet in
one location, which increases opportunities for
information exchange and consequent interference
with double-blinded procedures. We expect single-
center studies to be associated with lower placebo
and higher treatment effects.Intervention factors:
1. Type of PDE-5 inhibitor: expectations may be higher
for sildenafil since this was the first PDE-5 inhibitor
on the market.
Patient factors:
1. Prior PDE-5 inhibitor experience. Prior exposure to
effective pharmacological agents has been found to
produce very strong placebo responses in different
pathological conditions, such as Parkinson’s disease,
immune response, hormonal secretion, and
respiratory depression [20]. We expect prior PDE-5
inhibitor experience to be associated with lower
placebo effects and higher treatment effects.
In the case of considerable heterogeneity between
study results that cannot be explained by a priori de-
fined subgroup and meta-regression analyses, a series of
a posteriori meta-regression analyses will be performed
to identify sources of heterogeneity. A priori and a pos-
teriori analyses will be labeled as such.Sensitivity analyses
We will perform a sensitivity analysis for different as-
sumptions about missing data. We did not pre-specify
the random sequence generation risk-of-bias domain as
part of our formal definition of adequately blinded trials.
Therefore, we will conduct a sensitivity analysis by in-
cluding this characteristic in a meta-regression analysis.
Lastly, we will compare the results of fixed and random-
effects analyses.Discussion
This meta-epidemiological study will test the hypo-
thesis that unblinding in RCTs can raise expecta-
tions in intervention groups and lower expectations
in placebo groups. Additional subgroup analyses and
meta-regression will explore factors that can medi-
ate expectancies in RCTs with special emphasis on the
role of AEs. This information can be used to focus fu-
ture methodological and clinical research to better un-
derstand the nature and magnitude of expectancy in
health outcomes. Given the high cost of many treat-
ments and the cumulative risks of AEs, it is crucial to
address whether treatments are substantially more ef-
fective than expectancy alone. Methodological rigor in
the conduct and reporting of RCTs is especially im-
perative for those health conditions that are evaluated
subjectively, such as depression, ED, low back pain,
and other symptom driven complaints.
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To our knowledge, this will be the first study to investi-
gate enhanced placebo and nocebo effects in RCTs. We
will examine the impact of risk of bias due to unblinding
on a subjective continuous outcome for male ED and we
will seek confirmation of findings for an additional di-
chotomous outcome. Furthermore, this review will be
the first to explore the role of AEs in unblinding RCTs.
We will include crossover studies to improve the gen-
eralizability of our findings. Our methods will be rigor-
ous, including use of pre-defined screening forms,
pilot-tested data extraction and risk-of-bias forms, trained
reviewers with clinical or methodological expertize, and
a priori statistical analyses. We will prepare the review
according to the PRISMA statement [12].
One possible limitation of the review is that we will
use reported study data only, which may not be an ac-
curate representation of actual study conduct: reporting
can be poor but study conduct can be good, and vice
versa. Secondly, we are evaluating only one class of in-
tervention in the field of male sexual dysfunction, albeit
across a comprehensive set of studies. Lastly, we will not
search grey literature sources, which may result in some
relevant studies being missed. However, an assessment
of publication bias will provide an indication of whether
unpublished studies are absent from our evidence base.
Implications of the research
Clinical trials attempt to ascertain the specific isolated
effects of interventions. However, there is little quantita-
tive evidence available about the impact of non-specific
effects on outcomes. Consequently, these effects are gen-
erally ignored in clinical decisions. However, accumulat-
ing research demonstrates that non-specific effects are
real and significant, especially in subjectively assessed
medical conditions. The findings of this study will pro-
vide insight into the magnitude of non-specific treatment
effects in male ED. By quantifying nocebo and enhanced
placebo effect estimates, we hope that clinicians will be
able to incorporate such effects in treatment decisions
and patient counseling information. In addition, the re-
sults of this research may encourage further study of
non-specific effects for other types of ED interventions
and for other types of conditions.
Appendix 1
PubMed/MEDLINE search strategy
1. 30,50 cyclic GMP phosphodiesterase (MeSH terms)
2. phosphodiesterase 5 inhibitors (MeSH major topic)
3. phosphodiesterase* (title/abstract)
4. phospho-diesterase* (title/abstract)
5. pde 5 (title/abstract)
6. sildenafil (text word)7. viagra (text word)
8. vardenafil (text word)
9. levitra (text word)
10. tadalafil (text word)
11. cialis (text word)
12. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9
OR 10 OR 11
13. impotence (MeSH terms)
14. erecti* (title/abstract)
15. dysfunct* (title/abstract)
16. erect* (text word)
17. penile erection (MeSH terms)
18. sex* (title/abstract) AND 15
19. sex* (title/abstract) AND disorder* (title/abstract)
20. ((14 OR 16 OR 17) AND 15)
21. 13 OR 14 OR 16 OR 17 OR 18 OR 19 OR 20
22. randomized controlled trial (publication type)
23. controlled clinical trial (publication type)
24. randomized (title/abstract)
25. placebo (title/abstract)




30. 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29
31. animals (MeSH terms) not humans (MeSH terms)
32. 30 NOT 31
33. 2006/07/01 (date - publication): 3000
(date - publication)
34. 12 AND 21 AND 32 AND 33Appendix 2
Screening questions for titles and abstracts
Randomized study?
Placebo control?
One PDE5 inhibitor type?
Primarily erectile dysfunction?
Sildenafil, vardenafil, or tadalafil?
Has IIEF outcome?
Is the language of the article English, German, French,
or Dutch?Appendix 3
Study eligibility form
Is this study a randomized controlled trial (RCT)?
Does this study investigate one type of PDE-5 inhibitor?
Does this study have a placebo comparison group?
Report primarily on treatment of erectile dysfunction?
Report on efficacy of either sildenafil, tadalafil, or
vardenafil?
Report final assessment numerical data on IIEF-EF
change scores OR (final AND baseline IIEF-EF scores) for
placebo and intervention separately?
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All men are 18 years or older?
Appendix 4
Items to be included in the data abstraction forms








Total duration of the double-blind phase of the study
Single-center vs. multi-center






Blinding of outcome assessor
Blinding formally tested
Was ITT analysis performed?







Baseline ED severity IIEF-EF score
ED duration
Proportion of psychogenic ED etiology
PDE-5 inhibitor naive men
PDE-5 inhibitor responders
Interventions
Control or intervention ratio
Run-in period: duration, intervention
For intervention group:
Type of PDE-5 inhibitor
Regimen (fixed or flexible dose)
Dose
For both intervention and control groups:Compliance (number doses taken)Outcomes
For each outcome of interest:
Outcome definition
Unit of measurementResults
Baseline comparability of groups






Summary data for each intervention group
Estimate of effect with confidence interval; standard







Assumptions made (outcome and specification)
Miscellaneous comments by review authors
Abbreviations
AE: Adverse event; CI: Confidence interval; ED: Erectile dysfunction;
EF: Erectile functioning; FDA: Food and Drug Administration; GEQ: Global
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